Explore GPCR-targeting therapies and their untapped potential in drug development, making up 30-35 percent of approved drugs.

Historically, GPCRs have been one of the most important targets for drug discovery. In fact, around 30 % of all currently marketed drugs target GPCRs. Despite this, a significant number of GPCRs ...

Partnership combines AbTherx's proprietary Atlas™ Long CDR3 Technology with GPCR Therapeutics' deep expertise in GPCR biology to discover and develop antibodies for novel targets MOUNTAIN VIEW, CA / ...

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Partnership combines AbTherx's proprietary Atlas Long CDR3 Technology with GPCR Therapeutics' deep expertise in GPCR biology to discover and develop antibodies for novel targets MOUNTAIN VIEW, CA / AC ...

Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and ...

The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging ...

Salipro Biotech & Daewoong Pharmaceutical collaborate to advance development of novel therapeutics: Seoul, Korea Thursday, June 12, 2025, 16:00 Hrs [IST] Swedish biotech company S ...